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Macrolactam analogues of the natural lactone radicicol bind to Hsp90. 
 
Abstract 
A series of macrolactam analogues of the naturally occurring resorcylic acid lactone 
radicicol have been synthesised from methyl orsellinate in 7 steps, involving 
chlorination, protection of the two phenolic groups, and hydrolysis to the benzoic acid. 
Formation of the dianion and quenching with a Weinreb amide results in acylation of 
the toluene methyl group that is followed by amide formation and ring closing 
metathesis to form the macrocyclic lactam. Final deprotection of the phenolic groups 
gives the desired macrolactams whose binding to the N-terminal domain of yeast 
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Hsp90 was studied by isothermal titration calorimetry and protein X-ray 
crystallography. 
 
Introduction 
In recent years, the chaperone heat shock protein 90 (Hsp90) has become one of the 
most attractive and widely studied biological targets for molecular cancer 
therapeutics.1, 2 Ubiquitous in eukaryotic cells, Hsp90 utilises the energy released 
from ATP-hydrolysis to effect the maturation or activation of client proteins and has 
been found to play a pivotal role in numerous oncogenic pathways. More recently, the 
significance of Hsp90 has increased further following the discovery of its relevance in 
a number of other important medical conditions, ranging from neurodegenerative 
conditions,3-8 to HIV/AIDS,9-11 and malaria.12-14 As a result, significant research 
efforts have been devoted to discovering and synthesising potent small molecule 
inhibitors of Hsp90, a topic which has been the focus of many reviews.2, 9, 10, 15-22 
Seminal research in this area was centred on the natural products geldanamycin 1,23, 24 
a benzoquinone ansamycin polyketide, which has been the subject of previously 
published research from our group,25-27 and radicicol 2, a resorcylic acid lactone (RAL) 
first isolated in 1953,28 which is the most potent in vitro Hsp90 inhibitor found to date 
(IC50 =20−23 nM).29-31 Unfortunately, radicicol exhibits no in vivo activity, which 
may be due to the highly sensitive functionality present in the molecule, including an 
epoxide and a conjugated dienone, both of which are readily metabolised. As a result, 
significant efforts have focussed on synthesising radicicol analogues which retain the 
potency, yet are more metabolically stable (Figure 1).2 Having established the 
importance of the epoxide stereochemistry for good activity, Danishefsky and co-
workers replaced the C5-6 epoxide with a cyclopropyl group in order to improve the 
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stability of the molecule. Although a drop in potency was observed (IC50 = 160 nM  
vs. IC50 = 20-23 nM for radicicol), cycloproparadiciol 3 was still a very potent Hsp90 
inhibitor. It is noteworthy that the stereochemistry of the cyclopropyl group was also 
crucial for the activity. Additionally, the epoxide has been replaced with a thiirane,32 a 
cyclic carbonate,32 a diol32 and a carbon chain (both saturated and unsaturated).33 
Whilst the former three are significantly detrimental to the potency, a carbon chain is 
tolerated with only a two-fold drop in performance.33 The replacement of the dienone 
with more stable functionalities has also been investigated. Moody and Shinonaga 
have developed radicicol analogues with a C11 ketone and a either a saturated carbon 
chain from C7-C10 or an enone (4 and 5, respectively).32-34 Additionally, Danishefsky 
has replaced the dienone of cycloproparadicicol with a triazole 635 and we have also 
incorporated a triazole into the macrocycle (compound 7) to investigate the benefits of 
additional H-bonding potential.36 Unfortunately, it appears that the conformational 
constraints of RALs is important for binding to the Hsp90 N-terminal domain and, as 
such, all of the analogues showed a significant drop in activity compared to radicicol 
itself, although potencies commensurate with other important Hsp90 inhibitors were 
achievable.35 
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Figure 1. Radicicol analogue Hsp90 inhibitors.  
 
High throughput screening of simplified radicicol analogues, identified resorcinol-
containing diaryl pyrazoles as potent Hsp90 inhibitors.37 The hydrophobic group at 
C5 (alkyl or halide), along with two free phenols were found to be essential for a high 
binding affinity from SAR analysis, whilst the heterocycle was found to be variable, 
with isoxazoles, triazoles and benzisoxazoles also potent Hsp90 inhibitors.17, 22, 38, 39 
For such compounds, the heterocycle mimics the radicicol lactone unit, satisfying the 
same H-bonding interactions with the Hsp90 ATP-binding site. Lead optimisation 
gave compounds such as the resorcinol-pyrazole CCT018159 9 (IC50 = 7.1 µM), 
reported by Workman and colleagues.40, 41 Presently, there are currently four closely 
related compounds in clinical trials.2 These include ganetespib 10, owned by Synta 
Pharmaceuticals, administered intravenously, which has been evaluated in the clinic 
against non-small cell lung carcinoma and advanced solid tumours, and NVP-AU922 
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11, another intravenous drug owned by Vernalis-Novartis, which is currently in phase 
2 clinical trials.2 
 
 
Figure 2. Pyrazole and isoxazole-containing Hsp90 inhibitors.  
 
Our laboratory has been interested in developing novel Hsp90 inhibitors, including 
the synthesis of more potent and metabolically stable radicicol analogues, for some 
years.25-27, 33, 34, 36, 42, 43 As previously mentioned, despite still inhibiting Hsp90 
effectively, replacement of the dienone with a C-11 ketone and the epoxide with a 
double bond or a saturated hydrocarbon chain (compound 4) led to a 2-fold decrease 
in activity compared to radicicol itself,33 whilst the introduction of extra H-bonding, 
either at the 6-position, or from a triazole in the macrocycle,34, 36 gave a 
conformational change in the molecule and a loss in binding affinity. We also 
investigated the effect of varying the ring size and double bond position within the 
macrocycle and found that those analogues with 14 or 15-membered rings and the 
double bond located γ,δ- with respect to the lactone ring oxygen to be the most potent 
Hsp90 inhibitors, whilst a 12,13 or 16-membered ring gave depleted activity.33 More 
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recently, we investigated the synthesis of a series of resorcylic acid lactams as more 
metabolically stable radicicol analogues,43 a strategy widely employed in drug 
development and also utilised in the development of similar RAL analogues by 
Danishefsky93 and Winssinger.44 Our original synthetic route is outlined in Scheme 1: 
addition of the malonate-derived acid chloride 13 to anhydride 12 gave the acylated 
intermediate, which spontaneously underwent a cyclisation/retrocyclisation, with the 
loss of CO2, giving the isocoumarin 14 in 75% yield. This was readily converted into 
both the NH and NMe macrolactams 16 (see Figure 3 for bound X-ray structure) and 
17, respectively, and deprotection of the β-keto ester intermediate 15 also allowed for 
the incorporation of amide and ester functional groups at C10 (18 and 19, 
respectively), giving additional H-bonding potential. Pleasingly, the macrolactams 
were indeed more metabolically stable (43% metabolism for macrolactam 17 vs. 84% 
for radicicol after 15 minutes with human liver microsomes and NADH/NADPH) and 
significantly, were also often superior to the corresponding macrolactones in terms of 
activity.43  
 
Analysis of the Hsp90-bound protein structures of compounds 18 and 19 showed by 
X-ray crystallography that the C10 substituents displaced a loop between Leu93 and 
Lys98 in the ATP-binding site, allowing access to a further hydrophobic pocket, 
favourable for binding, and enhancing the biological properties of these analogues.43 
Since only one of these analogues contained a substituted lactam nitrogen, we wanted 
to extend our SAR and synthesise more of these analogues. We herein report a new 
and improved synthetic route to N-methylated resorcylic acid macrolactams, which is 
shorter and more convergent and allows us to vary the ring size and the position of the 
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double bond. We also report the binding of these analogues to Hsp90, as studied by 
protein crystallography. 
 
 
Scheme 1. Original synthesis of 14-membered macrolactams, analogues of the 
RALs.43 
 
 
Figure 3. Hsp90-bound X-ray crystal structure of macrolactam 16.43 Image from the 
article by Day et al.,43 reprinted, with permission from ACS Chem. Biol., 2011, 6, 
1339-1347. J. E. H. Day, S. Y. Sharp, M. G. Rowlands, W. Aherne, A. Hayes, F. I. 
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Raynaud, W. Lewis, S. M. Roe, C. Prodromou, L. H. Pearl, P. Workman, C. J. Moody, 
Copyright (2011) American Chemical Society. 
 
Results and Discussion 
The synthesis commenced from the methyl orsellinate 20, readily prepared via a self-
condensation of methyl acetoacetate.25 In our hands, the success of the previously 
reported45-47 sulfuryl chloride-mediated chlorination was found to be highly 
temperature dependent; a reaction temperature of −30 °C was crucial for selective 
monochlorination, with the product 21 isolated in 98% yield, whereas higher 
temperatures gave further chlorination. Protection of the resorcinol as the 
ethoxymethoxy ether proceeded smoothly, but saponification of the ester proved to 
particularly sluggish, with lengthy reaction times at reflux with potassium hydroxide 
required. Additionally, the orsellinic acid product 2334, 48 was incompatible with 
chromatography; any attempts led to deprotection of the hydroxyl group at the 6-
position. Instead, a carefully controlled work-up procedure was performed, washing 
the basic solution with organic solvent to remove any organic impurities, then rapid 
acidification and extraction of the pre-cooled solution to minimise any undesired 
deprotection. Satisfactory yields of 60-69% were achievable via this method. 
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Scheme 2. The synthesis of orsenillic acid 23 [EOM = ethoxymethyl]. 
 
With the key intermediate 23 in hand, our focus now turned to the amide coupling and 
benzylic acylation steps. With the option of varying the order of the two steps, we 
initially performed a HATU-mediated amide coupling with N-methylbut-3-en-1-
amine and obtained the product in quantitative yield. However, subsequent attempts 
to deprotonate and acylate the methyl group were unsuccessful with a variety of bases, 
additives and reaction conditions. We therefore turned to dianion chemistry, described 
previously in similar synthetic routes.49 Initial attempts to acylate the dianion formed 
from the treatment of orsellinic acid 23 with two equivalents of base (LDA or s-BuLi) 
were particularly low yielding, with only traces of product obtained and no 
purification possible without protecting group cleavage as described previously. 
Following significant investigative effort, it was established that the scale and 
concentration of the acylations were crucial for the success of the reaction. Following 
optimisation studies, the reactions were performed on scales in excess of 0.5 mmol of 
orsellinic acid, at a concentration of 0.2 M in THF at −78 °C, with the product 24 
being coupled with the relevant amine salt without further purification. This protocol 
gave satisfactory yields over two steps (Scheme 3). 
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Scheme 3. Acylation and coupling investigations. 
 
Interestingly, the products 25 exhibited magnetic inequivalence in the proton NMR 
spectrum, exemplified by the splitting of the benzylic protons, observed as a pair of 
roofed doublets (J = 17 Hz). We postulated that this is a result of the N-methyl group 
being sufficiently bulky to hinder the rotation past the lower chain chain, creating 
pairs of rotamers. 
 
The macrocycles were formed via ring closing metathesis, utilising Grubbs’ 2nd 
generation catalyst, in moderate to good yield and as mixtures of E/Z-isomers. 
Deprotection of the EOM groups proceeded smoothly with trifluoroacetic acid, giving 
the N-methyl resorcylic acid macrolactams 27 in up to 12% yield over four steps from 
the known precursor 23. The macrocycles were characterised as inseparable mixtures 
of E/Z-isomers, with the major component being the E-isomer in all cases with the 
exception of the 14-membered lactam 27d, which was predominantly the Z-isomer.  
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 Scheme 4. Formation of the radicicol analogues. 
 
Next, the thermodynamics of the binding of macrocycles 27b-d to Hsp90 was 
investigated through isothermal titration calorimetry (ITC) (Table 1). The results 
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show that there is a significant enthalpic penalty compared to radicicol, although the 
binding of the macrolactams was found to be superior to the macrolactone analogues 
we have previously described33 (Kd = 210-1200 µM). It should be noted that 
compounds 27b-d are mixtures of geometric isomers, albeit with heavy predominance 
of one isomer in each case, that makes interpretation of the binding data less clear. 
Nevertheless the data suggest that the interaction of the epoxide plays a significant 
role in the interaction with the protein. 
 
Ligand N Kd/µM ΔH/kJmol−1 ΔS/ J mol-1K-1 
Radicicol 1.16 0.015±0.06 -6726 13.6 
27b  1.0 (fixed) 144±25 -1012 14.2 
27c 0.92 41.8±8.7 -834.8 17.3 
27d 1.1 110±7.9 -1466 13.3 
Table 1. Isothermal titration calorimetry for macrolactams 27b-d with yeast Hsp90 N-
terminal domain (N = stoichiometry of binding). 
 
The radicicol analogues 27b-d were co-crystallised (major E/Z-isomer crystallised in 
all cases) with yeast Hsp90 in order to probe the interaction of the compounds with 
the Hsp90 N-terminal domain (Figure 4). The resorcylic acid macrolactams 27 bind to 
Hsp90 in a similar fashion to radicicol 2, with the same interactions exhibited by the 
resorcinol group in all cases. However, there is a clear conformational change in the 
macrocycle from radicicol to the macrolactams, emphasising the importance of the 
interaction between the radicicol epoxide and the Hsp90 backbone. For radicicol the 
electron density contoured at 1.5σ is clearly visible for the whole molecule. In 
contrast, for radicicol analogues 27b-d, electron density for the macrocycle was poor. 
Electron density contoured at 1.5σ for compound 27b and 27d was lacking for carbon 
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atoms 4 to 9 of the macrocycle ring. For compounds 27c the macrocycle was not 
represented by clear electron density for the carbon atoms 7 to 11.These observations 
are consistent with the idea that the epoxide group is important for radicicol binding. 
This is even more apparent on studying the overlay of radicicol 2 with the 
corresponding NH and NMe macrolactam analogues (17 and 27d, respectively), 
depicted in Figure 5. 
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Figure 4. Structures of resorcylic acid macrolactams (yellow) bound in the ATP site 
of yeast Hsp90 as determined by protein X-ray crystallography, showing the 
interactions of a radicicol 2 with Hsp90 (green and cyan residues); b, macrolactam 
27b (E-alkene) with Hsp90 (green and cyan residues); c, macrolactam 27c (E-alkene) 
with Hsp90 (green and cyan residues); d, macrolactam 27d (Z-alkene) with Hsp90 
(green and cyan residues). In general, the analogues exhibit a significant 
conformational change in the macrocycle. Dotted blue lines: hydrogen bonds, red-
coloured spheres: water molecules. The structures for radicicol and the macrolactam 
analogues were obtained at 2.5 (radicicol), 2.4 (27b), 2.0 (27c) and 2.3 Å(27d) 
resolution and the atomic coordinates and structure factors deposited with the 
following PDB codes 4ce2, 4ce1and 4ce3, respectively. 
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Figure 5. Overlaid crystal structures showing the difference in the conformation and 
binding of resorcylic acid macrolactams in comparison to radicicol. The different 
conformations of radicicol 2 (PDB code 1BGQ; green), NH macrolactam 16 (PDB 
code 2XX2; yellow)43 and NMe macrolactam 27d (PDB code 4ce3;cyan).  
 
In conclusion we have devised a route to, and successfully synthesised, a series of 
novel N-methyl macrolactam radicicol analogues as Hsp90 inhibitors. Their binding 
to Hsp90 was investigated and, despite diminished affinity compared to radicicol 
itself, the binding was found to be superior to the corresponding macrolactones. 
Importantly, details of the binding to Hsp90 inhibitors through co-crystallisation with 
the protein, with a change in the conformation of the macrocycle was observed.  
 
General Experimental Details 
Unless specified, all reagents were purchased from commercial sources and were used 
without further purification. Tetrahydrofuran was distilled from sodium-
benzophenone ketyl immediately before use. Water refers to deionised water, ether to 
diethyl ether, and light petroleum refers to the fraction with bp 40-60 °C. 
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Thin layer chromatography (TLC) was carried out using Merck Kieselgel 60GF254 
pre-coated aluminium-backed plates. The compounds were visualised using UV light 
(254 nm) and basic aqueous potassium permanganate solution, with heating. Flash 
column chromatography was performed at medium pressure using slurry packed 
Davisil silica gel 35-70 µm, 60 Å with the specified eluant. Silver nitrate-impregnated 
silica TLC plates were prepared by soaking the Merck Kieselgel 60GF254 pre-coated 
aluminium-backed plates in a 1:3 w/v solution of AgNO3 in MeCN for 5 min, before 
being dried in an oven at 150 °C for 10 min. The TLC plates were covered in 
aluminium foil and stored in the dark. Compounds were visualised with basic aqueous 
potassium permanganate solution and heating. 
 
Infrared spectra were obtained on a Perkin Elmer 1600 series FT-IR spectrometer 
using NaCl solution cells in chloroform or acetone. 1H NMR and 13C NMR spectra 
were obtained using a JEOL EX270 operating at 270 MHz (13C 67.5 MHz), or Bruker 
Avance III-400, Bruker Avance 400 or Bruker DPX 400 spectrometers operating at 
400 MHz (13C 100 MHz). All spectroscopic data was recorded at 295K. Chemical 
shifts are quoted in parts per million (ppm), using the residual solvent peak as an 
internal standard (7.26 ppm [1H NMR] and 77.2 ppm [13C NMR] for CDCl3 and 2.05 
ppm [1H NMR] and 206.7, 29.9 ppm [13C NMR] for acetone-d6). Coupling constants 
(J) are quoted in Hz. Multiplicity abbreviations used: s singlet, d doublet, t triplet, q 
quartet, m multiplet. Signal assignment was achieved via analysis of DEPT, COSY, 
HMBC and HSQC experiments where needed. 1H NMR and 13C NMR spectra of final 
compounds were performed on a Bruker AV(III)800 at 800 and 200 MHz, 
respectively. Low and high-resolution mass spectra were performed for all novel 
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compounds. Electrospray ionisation (ESI) and high resolution mass spectrometric 
(HRMS) analyses were performed on a Bruker MicroTOF spectrometer. 
 
Methyl 2,4-dihydroxy-6-methylbenzoate 2025 
 
Sodium hydride (20.67 g, 0.52 mol, 1.5 eq.) was prewashed with pentane (3 × 50 mL), 
before being suspended in THF (800 mL) and cooled to 0 °C under argon. Methyl 
acetoacetate (40.00 g, 0.34 mol, 1.0 eq.) was added dropwise over 2 h and the reaction 
mixture was warmed to room temperature over 1 h. After cooling to −78 °C, n-
butyllithium (130.90 mL, 327.25 mmol, 0.95 eq.) was added via cannula over 1 h and 
the solution was allowed to warm to room temperature over 16 h, before being heated 
under reflux for 24 h. The mixture was re-cooled to 0 °C and hydrochloric acid (1 M; 
400 mL) was added cautiously, the aqueous layer was acidified to pH 1 with 
concentrated hydrochloric acid and the mixture was warmed to room temperature and 
stirred for 18 h. The layers were separated and the aqueous layer was washed with 
ethyl acetate (2 × 400 mL). The combined organics were washed with water (400 mL) 
and saturated brine (400 mL), before being dried over magnesium sulfate and 
concentrated in vacuo. The residue was purified by recrystallisation (ethyl 
acetate/light petroleum) to give the title compound as a light brown, crystalline solid 
(16.31 g, 52%); δH (400 MHz; CDCl3) 11.41 (1H, s, OH), 6.53 (1H, s, ArH), 6.08 (1H, 
s, ArH), 5.09 (1H, br. s, OH),  3.95 (3H, s, OMe), 2.63 (3H, s, CH3); δC (100 MHz; 
CDCl3) 171.4 (C), 162.9 (C), 156.0 (C), 139.5 (C), 107.1 (C), 102.0 (CH), 52.3 (Me), 
30.9 (CH), 19.9 (Me); data consistent with those reported in the literature.25 
 
17 
Methyl 3-chloro-4,6-dihydroxy-2-methylbenzoate 21 
 
To a solution of methyl 2,4-dihydroxy-6-methylbenzoate 20 (5.73 g, 31.48 mmol, 1.0 
eq.) in THF (315 mL) at −30 °C was added sulfuryl chloride (2.78 mL, 34.62 mmol, 
1.1 eq.) slowly over 5 min, keeping the temperature between −20 and −30 °C 
throughout. After stirring for a further 30 min, the reaction mixture was quenched 
with ammonium chloride (200 mL) and the layers were stirred and separated. The 
aqueous layer was extracted with ether (2 × 200 mL) and the combined organics were 
washed with saturated brine (2 × 200 mL), before being dried over sodium sulfate and 
concentrated in vacuo to give a yellow solid. The product was purified by 
recrystallisation (dichloromethane/light petroleum) to give the title compound as a 
colourless solid (6.651 g, 98%); mp 133-135 °C (lit,50 mp 134 °C); δH (270 MHz, 
CDCl3) 11.41 (1H, s, 6-OH), 6.52 (1H, s, H-5), 6.03 (1H, s, 4-OH), 3.31 (3H, s, OMe), 
2.61 (3H, s, Me); δC  (100 MHz, CDCl3) 171.4 (C), 162.9 (C), 156.0 (C), 139.5 (C), 
113.9 (C), 107.1 (C), 102.0 (CH), 52.3 (Me), 19.9 (Me). Data consistent with those 
reported in the literature.45 
 
Methyl 3-chloro-4,6-di(ethoxymethoxy)-2-methylbenzoate 22 
 
To a solution of methyl 3-chloro-4,6-dihydroxy-2-methylbenzoate 21 (7.03 g, 32.52 
mmol, 1.0 eq.) in dimethylformamide (108 mL) at 0 °C under argon was added ethyl 
chloromethyl ether (7.54 mL, 81.29 mmol, 2.5 eq.). N,N-Diisopropylethylamine 
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(16.99 mL, 97.55 mmol, 3.0 eq.) was added slowly and the reaction mixture was 
stirred for 30 min, before being allowed to warm to room temperature and stirred for a 
further 2 h. Saturated aqueous ammonium hydroxide solution (100 mL) was added 
and the reaction mixture was stirred for a further 10 min, before being extracted with 
ether (3 × 100 mL). The combined organics were washed with aqueous lithium 
chloride solution (5%; 3 × 100 mL), dried over magnesium sulfate and concentrated 
in vacuo to give a yellow oil. The product was purified by flash column 
chromatography, eluting with 9:1 light petroleum/ethyl acetate to give the title 
compound as a colourless oil (10.37 g, 96%); (Found: M+Na+, 355.0916. 
C15H2135ClO6+Na+, requires 355.0919); νmax (CHCl3)/cm−1 3526, 2981, 2955, 1728, 
1660, 1596, 1476, 1433, 1321, 1265, 1114, 1042, 963, 932, 844; δH (400 MHz; CDCl3) 
7.02 (1H, s, ArH), 5.32 (2H, s, OCH2O), 5.22 (2H, s, OCH2O), 3.93 (3H, s, OMe), 
3.82-3.76 (2H, q, J = 7.0, OCH2), 3.76-3.71 (2H, q, J = 7.0, OCH2), 2.34 (3H, s, Me), 
1.27-1.23 (3H, t, J = 7.0, CH3), 1.26-1.22 (3H, t, J = 7.0, CH3); δC (100 MHz; CDCl3) 
167.9 (C), 154.3 (C), 153.1 (C), 135.1 (C), 119.8 (C), 117.1 (C), 101.7 (CH), 93.8 
(CH2), 93.8 (CH2), 64.6 (CH2), 64.4 (CH2), 52.3 (Me), 17.5 (Me), 15.0 (Me), 15.0 
(Me); m/z (ESI) 355 ([M(35Cl)+Na]+, 100%), 357 (33.0%). 
 
3-Chloro-4,6-di(ethoxymethoxy)-2-methylbenzoic acid 23 
 
To a stirred solution of methyl 3-chloro-4, 6-di(ethoxymethoxy)-2-methylbenzoate 22 
(6.26 g, 18.82 mmol, 1.0 eq.) in 1:1 methanol/water (60 mL) was added potassium 
hydroxide (5.28 g, 94.09 mmol, 5.0 eq.) and the reaction mixture was heated to 70 °C 
19 
and stirred for 3 d. After cooling to room temperature, water (50 mL) was added and 
the mixture was extracted with ethyl acetate (50 mL). The aqueous layer was cooled 
to 0 °C, acidified to pH 1 with concentrated hydrochloric acid and quickly extracted 
with ethyl acetate (3 × 75 mL). The combined organic extracts were washed with 
brine (100 mL), dried over magnesium sulfate and concentrated in vacuo to give the 
title compound as a colourless solid (4.15 g, 69%); mp 78-80 °C; (Found: C, 52.8; H, 
6.0.%. C14H1935ClO6, requires C, 52.8; H, 6.0%); δH (400 MHz; acetone-d6) 7.10 (1 H, 
s, ArH), 5.36 (2H, s, OCH2O), 5.27 (2 H, s, OCH2O), 3.78 (2H, q, J 7.1, OCH2), 3.73 
(2H, q, J 7.1, OCH2), 2.36 (3 H, s, Me), 1.21 (3H, t, J 7.1, Me), 1.19 (3H, t, J 7.1, Me); 
δC (100 MHz; acetone-d6) 169.1 (C), 154.9 (C), 153.7 (C), 136.9 (C), 117.8 (C), 110.0 
(C), 101.7 (CH), 94.3 (CH2), 93.8 (CH2), 64.8 (CH2), 64.8 (CH2), 17.9 (Me), 15.0 
(Me), 15.0 (Me). Data consistent with those reported in the literature.31 
 
N-(But-3-en-1-yl)-3-chloro-4,6-di(ethoxymethoxy)-N-methyl-2-(2-oxooct-7-en-1-
yl)benzamide 25a 
 
To a solution of 3-chloro-4,6-di(ethoxymethoxy)-2-methylbenzoic acid 23 (170 mg, 
0.54 mmol, 1.0 eq.) in THF (2.67 mL) in an oven dried flask at −78 °C was added 
sec-butyllithium (1.08 mL, 1.19 mmol, 2.2 eq.). The resulting red solution was stirred 
for 40 min before a solution of N-methoxy-N-methylhept-6-enamide (138 mg, 0.81 
mmol, 1.5 eq.) in THF (0.3 mL) was added. The reaction mixture was stirred for a 
further 50 min at −78 °C. Water (5 mL) was added and the solution was washed with 
ether (2 × 5 mL). The aqueous layer was acidified to pH 1 with hydrochloric acid (1 
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M; 5 mL) and extracted with ethyl acetate (3 × 5 mL). The combined organics were 
dried over magnesium sulfate and concentrated in vacuo to give a yellow oil (171 
mg,). The crude material was used without further purification. 3-Chloro-4,6-
di(ethoxymethoxy)-2-(2-oxooct-7-en-1-yl)benzoic acid (171 mg, 0.40 mmol 1 eq.) 
was dissolved in DMF (2 mL). To the reaction solution was added N-methylbut-3-en-
1-amine hydrochloride (73 mg, 0.60 mmol, 1.5 eq.), N,N-diisopropylethylamine (2.15 
mL, 1.60 mmol, 4.0 eq.) and HATU (174 mg, 0.46 mmol, 1.15 eq.). The reaction 
mixture was stirred at room temperature for 18 h. A further 0.2 equivalents of N-
methylbut-3-en-1-amine hydrochloride (10 mg) and 0.1 equivalents of HATU (15 mg) 
were added and the reaction mixture was stirred for a further 3 h. The solution was 
diluted with ethyl acetate (10 mL) and washed with hydrochloric acid (1 M; 5 mL), 
saturated aqueous sodium hydrogen carbonate (5 mL) and brine (5 mL). The organic 
layer was dried over magnesium sulfate and concentrated in vacuo to give a yellow oil. 
The residue was purified by flash column chromatography, eluting with 4:1, then 2:1 
light petroleum/ethyl acetate to give the title compound as a colourless oil (0.056g, 
33% over 2 steps) (3:1 mixture of isomers); (Found: M+Na+, 518.2287. 
C26H3835ClNO6+Na+, requires 518.2280); νmax (CHCl3)/cm−1 3665, 3079, 3001, 1759, 
1628, 1590, 1486, 1453, 1327, 1244, 1054, 1036, 1029; major isomer δH (400 MHz; 
CDCl3) 7.08 (1H, s, ArH), 5.89-5.73 (2H, m, CH), 5.29 (1H, d, J 12.8, OCH2O), 5.27 
(1H, d, J 12.8, OCH2O), 5.18 (2H, s, OCH2O), 5.14-4.92 (4H, m, =CH2), 3.98 (1H, d, 
J 17.6, CH2), 3.79 (1H, d, J 17.6, CH2), 3.80-3.73 (2H, m, OCH2), 3.72-3.66 (2H, m, 
OCH2), 3.57 (1H, dt, J 13.1, 6.8, CH2), 2.83 (3H, s, NMe), 2.54-2.48 (2H, m, CH2), 
2.39-2.34 (2H, m, CH2), 2.08-2.04 (2H, m, CH2), 1.65-1.57 (3H, m, CH2), 1.43-1.36 
(2H, m, CH2),1.23 (6H, 2 × t, J 14.5, 7.1, Me); δC (100 MHz; CDCl3) 206.5 (C), 
167.6 (C), 153.8 (C), 152.1 (C), 138.5 (CH), 135.4 (CH), 134.7 (C), 132.3 (C), 122.8 
21 
(C),  116.6 (CH2), 114.6 (CH2), 102.5 (CH), 94.0 (CH2), 93.7 (CH2), 64.6 (CH2), 64.4 
(CH2), 46.6 (CH2), 44.9 (CH2), 42.5 (CH2), 36.1 (Me),  33.5 (CH2), 31.6 (CH2), 28.3 
(CH2), 23.2 (CH2), 15.0 (Me), 15.0 (Me); for the minor isomer, the following NMR 
signals are discernable, the rest overlap with the major isomer: δH (400 MHz; CDCl3) 
7.12 (1H, s, ArH), 5.68-5.56 (2H, m, CH), 5.30 (1H, d, J 15.1, O-CH2-O), 5.28 (1H, d, 
J 15.1, O-CH2-O), 3.87 (1H, d, J 17.5, CH2), 3.04 (3H, s, NMe), 2.26-2.21 (2H, m, 
CH2); δC (100 MHz; CDCl3) 117.7 (CH2), 117.0 (CH2), 102.7 (CH), 64.5 (CH2), 50.2 
(CH2), 45.3 (CH2), 42.2 (CH2), 32.6 (CH2), 32.2 (CH2); m/z (ESI) 518 ([M(35Cl)+Na]+, 
100%), 519 (27.0%), 520 (35.6%), 521 (9.5%). 
 
13-Chloro-14,16-di(ethoxymethoxy)-2-methyl-3,4,7,8,9,10-
hexahydrobenz[c][1]azacyclotetradecine-1,11(2H,12H)-dione 26a 
 
A solution of N-(but-3-en-1-yl)-3-chloro-4,6-di(ethoxymethoxy)-N-methyl-2-(2-
oxooct-7-en-1-yl)benzamide 25a (56 mg, 0.11 mmol, 1.0 eq.) dichloromethane (35 
mL) was sparged with nitrogen and Grubbs II catalyst (11 mg, 0.01 mmol, 0.11 eq.) 
was added. The reaction mixture was heated to reflux for 90 min. After cooling to 
room temperature, DMSO (0.1 mL) was added and the solution was stirred for 18 h. 
The reaction mixture was concentrated in vacuo and purified by flash column 
chromatography, eluting with 4:1 light petroleum/ethyl acetate to give the title 
compound as a colourless oil (0.027 g, 51%) (4:1 mixture of E/Z isomers); (Found: 
M+Na+, 490.1956. C24H3435ClNO6+Na+, requires 490.1967); νmax (CHCl3)/cm−1 3011, 
2928, 2855, 1720, 1624, 1592, 1464, 1323, 1239, 1118, 1045, 929; major isomer δH 
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(400 MHz; CDCl3) 7.10 (1H, s, ArH), 5.57-5.39 (2H, m, CH=CH), 5.30 (1H, d, J 15.1, 
OCH2O), 5.28 (1H, d, J 15.1, OCH2O), 5.22-5.18 (2H, m, OCH2O), 4.56 (1H, ddd, J 
19.1, 9.6, 5,6, CH2), 4.03 (1H, d, J 17.9, CH2), 3.85 (1H, d, J 17.9, CH2), 3.78 (2H, dq, 
J 14.2, 7.1, OCH2), 3.70 (2H, dq, J 14.2, 4.1, OCH2), 2.77 (3H, s, NMe), 2.68 (1H, 
ddd, J 16.9, 7.9, 1.9, CH2), 2.59-2.50 (1H, m, CH2), 2.46-2.31 (3H, m, CH2), 2.20-
2.11 (1H, m, CH2), 2.07-1.99 (1H, m, CH2), 1.83-1.75 (1H, m, CH2), 1.68-1.59 (1H, 
m, CH2) 1.56-1.47 (2H, m, CH2), 1.23 (6H, 2 × t, J 8.8, 7.1, Me), 0.97-0.88 (1H, m, 
CH2); δC (100 MHz; CDCl3) 205.8 (C), 168.2 (C), 153.7 (C), 152.0 (C), 132.7 (CH), 
132.0 (C), 128.4 (CH), 123.0 (C), 117.9 (C), 102.7 (CH), 93.9 (CH2), 93.7 (CH2), 
64.5 (CH2), 64.4 (CH2), 46.3 (CH2), 44.8 (CH2), 40.4 (CH2), 36.1 (Me), 30.4 (CH2), 
30.2 (CH2), 26.2 (CH2), 21.6 (CH2), 15.0 (Me), 15.0 (Me); for the minor isomer, the 
following NMR signals are discernable, the rest overlap with the major isomer: δH 
(400 MHz; CDCl3) 7.11 (1H, s, ArH), 4.06 (1H, d, J 18.1, CH2), 3.95 (1H, d, J 18.1, 
CH2), 2.82 (3H, s, NMe); δC (100 MHz; CDCl3) 206.2 (C), 151.9 (C), 132.2 (CH), 
131.2 (C), 129.3 (CH), 102.6 (CH), 47.3 (CH2), 44.6 (CH2), 41.6 (CH2), 37.1 (Me), 
29.7 (CH2), 27.3 (CH2), 25.4 (CH2), 21.9 (CH2); m/z (ESI) 490 ([M(35Cl)+Na]+, 
100%), 492 (33.0 %). 
 
13-Chloro-14,16-dihydroxy-2-methyl-3,4,7,8,9,10-
hexahydrobenzo[c][1]azacycletetradecine-1,11(2H,12H)-dione 27a1 
 
To a solution of 13-chloro-14,16-di(ethoxymethoxy)-2-methyl-3,4,7,8,9,10-
hexahydrobenzo[c][1]azacyclotetradecine-1,11(2H,12H)-dione 26a (13 mg, 0.03 
mmol, 1.0 eq.) in dichloromethane (2 mL) was added trifluoroacetic acid (0.32 mL, 
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0.04 mmol, 1.5 eq.) and the reaction mixture was stirred at room temperature for 30 
min. Saturated aqueous sodium hydrogen carbonate (5 mL) was added and the 
mixture was extracted with ethyl acetate (3 × 10 mL). The combined organics were 
washed with saturated brine (10 mL), dried over sodium sulfate and concentrated in 
vacuo to give a yellow oil. The residue was purified by flash column chromatography, 
eluting with 1% methanol/dichloromethane to give a colourless oil (7 mg, 72%) (9:1 
mixture of isomers); major isomer δH (400 MHz; CDCl3) 8.66 (1H, br. s, OH), 6.55 
(1H, s, ArH), 5.51 (2H, dt, J 15.4, 9.0, CH=CH), 4.46 (1H, ddd, J 13.3, 9.3, 3.9, CH2), 
3.89 (2H, s, CH2), 2.94-2.83(1H, m, CH2), 2.81 (3H, s, NMe), 2.77 (1H, ddd, J 13.6, 
6.4, 3.8, CH2), 2.61 (1H, ddd, J 16.3, 8.1, 2.0, CH2), 2.52-2.33 (3H, m, CH2), 2.15-
2.09 (1H, m, CH2), 1.74 (1H, m, CH2), 1.68-1.58 (1H, m, CH2), 1.53-1.46 (2H, m,  
CH2); δC (100 MHz; CDCl3) 204.8 (C), 167.9 (C), 153.3 (C), 152.2 (C), 132.0 (CH), 
129.1 (CH), 119.7 (C), 110.2 (C), 109.9 (C), 102.2 (CH), 46.8 (CH2), 44.2 (CH2), 
40.2 (CH2) 35.1 (Me), 30.3 (CH2), 30.1 (CH2), 26.3 (CH2), 21.5 (CH2); for the minor 
isomer, the following NMR signals are discernable, the rest overlap with the major 
isomer: δH (400 MHz; CDCl3) 6.57 (1H, s, ArH), 5.58-5.44 (2H, m, CH=CH), 4.06 
(1H, ddd, J 14.3, 8.05, 2.88, CH2), 3.97, (2H, d, J 9.3, CH2) 2.82 (3H, s, Me); δC (100 
MHz; CDCl3) 130.7 (CH), 44.1 (CH2). Data consistent with those reported in the 
literature.1 
 
N-(But-3-en-1-yl)-3-chloro-4,6-di(ethoxymethoxy)-N-methyl-2-(2-oxonon-8-en-1-
yl)benzamide 25b 
 
24 
As for the procedure for compound 25a, using 3-chloro-4,6-di(ethoxymethoxy)-2-
methylbenzoic acid 23 (200 mg, 0.63 mmol, 1.0 eq.), N-methoxy-N-methyloct-7-
enamide (187 mg, 0.94 mmol, 1.5 eq), N-methylbut-3-en-1-amine hydrochloride (63 
mg, 0.52 mmol, 1.5 eq), N,N-diisopropylethylamine (0.24 mL, 1.38 mmol, 4.0 eq.) 
and HATU (151 mg, 0.40 mmol, 1.15 eq.). The product was purified by flash column 
chromatography, eluting with 4:1 light petroleum/ethyl acetate to give the title 
compound as a colourless oil (0.070 g, 25% over 2 steps) (3:1 mixture of isomers); 
(Found: M+Na+, 532.2442. C27H4035ClNO6+Na+, requires 532.2436); νmax 
(CHCl3)/cm−1 3685, 3001, 2930, 1719, 1630, 1596, 1466, 1407, 1321, 1274, 1264, 
1151, 1120, 910; major isomer δH (400 MHz; CDCl3) 7.08 (1H, s, ArH), 5.93-5.74 
(2H, m, CH), 5.29 (1H, d, J 13.0, OCH2O), 5.27 (1H, d, J 13.0, OCH2O), 5.20-5.16 
(2H, m, OCH2O), 5.14-4.91 (4H, m, =CH2), 3.98 (1H, d, J 17.7, CH2), 3.79 (1H, d, J 
17.7, CH2), 3.80-3.74 (2H, m, OCH2), 3.72-3.66 (2H, m, OCH2), 2.83 (3H, s, NMe), 
2.50 (2H, dt, J 12.2, 7.2, CH2), 2.39-2.34 (2H, m, CH2), 2.26-2.20 (1H, m, CH2), 
2.06-2.01 (3H, m, CH2), 1.64-1.57 (2H, m, CH2), 1.37 (2H, ddd, J 14.9, 8.6, 2.7, CH2), 
1.34-1.28 (2H, m, CH2), 1.23 (6H, 2 × t, J 14.5, 7.3, Me); δC (100 MHz; CDCl3) 
196.5 (C), 167.6 (C), 138.8 (C), 138.7 (C), 135.4 (C), 135.0 (C), 134.8 (C), 116.6 
(CH2), 114.4 (CH2), 110.6 (CH), 102.6 (CH), 102.5 (CH) 94.0 (CH2), 93.7 (CH2), 
64.6 (CH2), 64.4 (CH2), 46.5 (CH2), 44.8 (CH2), 42.6 (CH2), 36.1 (Me),  33.6 (CH2), 
31.6 (CH2), 28.7 (CH2), 28.6 (CH2), 23.6 (CH2), 15.0 (Me), 15.0 (Me); for the minor 
isomer, the following NMR signals are discernable, the rest overlap with the major 
isomer: δH (400 MHz; CDCl3) 6.98 (1H, s, ArH), 5.68-5.55 (2H, m, CH), 5.30 (1H, d, 
J 15.3, OCH2O), 5.28 (1H, d, J 15.3, OCH2O), 3.88 (1H, d, J 17.5, CH2), 3.57 (2H, dq, 
J 13.6, 9.4,  OCH2), 2.81 (3H, s, NMe), 1.27-1.16 (6H, m, Me); m/z (ESI) 532 
([M(35Cl)+Na]+, 100%), 533 (34.6%), 534 (36.1%), 535 (10.5%). 
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14-Chloro-15,17-di(ethoxymethoxy)-2-methyl-3,4,7,8,9,10,11,13-octahydro-1H-
benzo[c][1]azacyclopentadecine-1,12(2H)-dione 26b 
 
As for the procedure for compound 26a, using N-(but-3-en-1-yl)-3-chloro-4,6-
di(ethoxymethoxy)-N-methyl-2-(2-oxonon-8-en-1-yl)benzamide 25b (70 mg, 0.14 
mmol, 1.0 eq.). The product was purified by flash column chromatography, eluting 
with 2:1 light petroleum/ethyl acetate to give the title compound as a colourless oil 
(0.026 g, 39%) (2:1 mixture of isomers); (Found: M+Na+, 504.2124. 
C25H3635ClNO6+Na+, requires 504.2123); νmax (CHCl3)/cm−1 3686, 3600, 2928, 2855, 
1717, 1605, 1465, 1286, 1269, 1044, 910; major isomer δH (400 MHz; CDCl3) 7.10 
(1H, s, ArH), 5.48-5.35 (2H, m, CH=CH), 5.30 (1H, d, J 16.6, OCH2O), 5.28 (1H, d, 
J 16.6, OCH2O), 5.22-5.18 (2H, m, OCH2O), 4.64 (1H, ddd, J 14.9, 9.4, 5.9, CH2), 
4.13 (1H, d, J 18.0, CH2), 3.83-3.74 (2H, m, OCH2), 3.73-3.67 (2H, m, OCH2), 3.69 
(1H, d, J 18.0, CH2), 2.83 (3H, s, NMe), 2.82-2.73 (2H, m, CH2), 2.48-2.33 (3H, m, 
CH2), 2.09-2.00 (2H, m, CH2), 1.87-1.75 (1H, m, CH2), 1.63-1.52 (1H, m, CH2), 1.46-
1.32 (4H, m, CH2), 1.24 (6H, 2 × t, J 13.1, 7.1, Me); δC (100 MHz; CDCl3) 207.5 (C), 
168.8 (C), 153.7 (C), 152.2 (C), 132.5 (C), 132.3 (CH), 127.7 (CH), 123.7 (C), 117.4 
(C), 102.7 (CH), 94.0 (CH2), 93.8 (CH2), 64.6 (CH2), 64.5 (CH2), 45.7 (CH2), 45.5 
(CH2), 42.2 (CH2), 34.6 (Me), 30.8 (CH2), 29.9 (CH2), 26.7 (CH2), 25.9 (CH2), 23.4 
(CH2), 15.1 (Me), 15.0 (Me); for the minor isomer, the following NMR signals are 
discernable, the rest overlap with the major isomer: δH (400 MHz; CDCl3) 7.11 (1H, s, 
ArH), 5.31 (1H, d, J 17.3, OCH2O), 5.29 (1H, d, J 17.3, OCH2O), 4.14 (1H, d, J 18.8, 
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CH2), 3.27-3.19 (2H, m, CH2), 3.11-3.06 (1H, m, CH2), 2.64-2.56 (1H, m, CH2), 2.18-
2.09 (2H, m, CH2), 1.99-1.91 (2H, m, CH2); δC (100 MHz; CDCl3) 207.0 (C), 154.1 
(C), 152.7 (C), 133.3 (C), 131.8 (CH), 128.4 (CH), 122.4 (C), 118.2 (C), 102.4 (CH), 
94.1 (CH2), 94.0 (CH2), 48.0 (CH2), 46.8 (CH2), 41.2 (CH2), 31.1 (CH2), 29.0 (CH2), 
26.0 (CH2), 25.2 (CH2), 22.0 (CH2); m/z (ESI) 504 ([M(35Cl)+Na]+, 100%), 505 
(23.4%), 506 (32.4%), 507 (8.4%). 
14-Chloro-15,17-dihydroxy-2-methyl-3,4,7,8,9,10,11,13-octahydro-1H-
benz[c][1]azacyclopentadecine-1,12(2H)-dione 27b 
 
As for the procedure for compound 27a, using 14-chloro-15,17-di(ethoxymethoxy)-2-
methyl-3,4,7,8,9,10,11,13-octahydro-1H-benzo[c][1]azacyclopentadecine-1,12(2H)-
dione 26b (26 mg, 0.05 mmol, 1 eq.). Product purified by flash column 
chromatography, eluting with 2% methanol/dichloromethane to give the title 
compound as a colourless solid (9 mg, 45%) (3:1 mixture of isomers); mp 102-104 °C; 
(Found: M+Na+, 388.1296. C19H2435ClNO4+Na+, requires 388.1286); νmax 
(CHCl3)/cm−1 3438, 3274, 2859, 1732, 1728, 1701, 1623, 1455, 1445, 1391, 1343, 
1312, 1251, 1100; major isomer δH (800 MHz; acetone-d6) 8.69 (1H, br. s, OH), 7.97 
(1H, s, OH), 6.55 (1H, s, ArH), 5.46-5.41 (1H, m, CH), 5.40-5.34 (1H, m, CH), 4.51 
(1H, ddd, J 14.7, 11.9, 3.4, CH2), 3.98 (1H, d, J 17.9, CH2), 3.76 (1H, d, J 17.9 CH2), 
2.94 (3H, s, NMe), 2.75-2.71 (2H, m, CH2), 2.45-2.40 (1H, m, CH2), 2.38-2.33 (1H, 
m, CH2), 1.80-1.75 (1H, m, CH2), 1.59-1.54 (1H, m, CH2), 1.42-1.36 (2H, m, CH2), 
1.32-1.27 (3H, m, CH2), 1.24-1.15 (2H, m, CH2); δC (200 MHz; acetone-d6) 208.0 (C), 
170.2 (C), 163.7 (C), 154.2 (C), 134.9 (C), 133.3 (CH), 130.1 (CH), 122.3 (C)  114.2 
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(C), 104.1 (CH), 47.1 (CH2), 47.0 (CH2), 46.9 (CH2), 43.5 (CH2), 37.1 (Me), 35.6 
(CH2), 28.6 (CH2),  27.6 (CH2), 25.2 (CH2); for the minor isomer, the following NMR 
signals are discernable, the rest overlap with the major isomer: δH (800 MHz; acetone-
d6) 5.27-5.21 (1H, m, CH), 5.22-5.19 (1H, m, CH), 4.38 (1H, ddd, J 14.7, 11.9, 3.4, 
CH2), 4.16 (1H, d, J 18.8, CH2), 3.99 (1H, d, J 18.8 CH2), 2.88 (3H, s, NMe), 2.62-
2.56 (2H, m, CH2), 1.94-1.88 (1H, m, CH2); δC (200 MHz; acetone-d6) 207.9 (C), 
170.1 (C), 155.2 (C), 133.1 (CH), 131.2 (CH), 101.9 (CH), 49.3 (CH2), 47.8 (CH2), 
42.6 (CH2), 32.4 (CH2), 28.1 (CH2), 26.8 (CH2), 23.6 (CH2); m/z (ESI) 388 
([M(35Cl)+Na]+, 100%), 389 (18.6%), 390 (31.6%), 391 (5.8%). 
N-(But-3-en-1-yl)-3-chloro-4,6-di(ethoxymethoxy)-N-methyl-2-(2-oxodec-9-en-1-
yl)benzamide 25c 
 
As for the procedure for compound 25a, using 3-chloro-4,6-bis(ethoxymethoxy)-2-
methylbenzoic acid 23 (200 mg, 0.63 mmol, 1.0 eq.), N-methoxy-N-methylnon-8-
enamide (174 mg, 0.94 mmol, 1.5 eq.), N-methylbut-3-en-1-amine hydrochloride (74 
mg, 0.61 mmol, 1.5 eq.). The product was purified by flash column chromatography, 
eluting with 4:1 light petroleum/ethyl acetate to give the title compound as a 
colourless oil (0.051 g, 16% over 2 steps) (4:1 mixture of isomers); (Found: M+Na+, 
546.2590 C28H4235ClNO6+Na+, requires 546.2593); νmax (CHCl3)/cm−1 3742, 3678, 
3050, 2999, 2872, 1631, 1464, 1380, 1366, 1276, 1259, 1172, 1149, 1126, 1039, 851;  
major isomer δH (400 MHz; CDCl3) 7.11 (1H, s, ArH), 5.92-5.77 (2H, m, CH), 5.32 
(1H, d, J 13.0, OCH2O), 5.30 (1H, d, J 13.0, OCH2O), 5.23-5.19 (2H, m, OCH2O), 
5.16-4.94 (4H, m, =CH2), 4.02 (1H, d, J 17.7, CH2), 3.82 (1H, d, J 17.7, CH2), 3.83-
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3.76 (2H, m, OCH2), 3.75-3.68 (2H, m, OCH2), 3.64-3.53 (1H, dt, J 15.6, 9.4, CH2), 
2.86 (3H, s, NMe), 2.52 (2H, ddd, J 15.1, 7.1, 1.1, CH2), 2.42-2.37 (1H, m, CH2), 
2.35-2.24 (2H, m, CH2), 2.09-2.03 (2H, m, CH2), 1.67-1.56 (2H, m, CH2), 1.44-1.37 
(3H, m, CH2), 1.36-1.30 (3H, m, CH2), 1.23 (6H, 2 × t, J 14.5, 7.3, Me); δC (100 MHz; 
CDCl3) 206.6 (C), 167.5 (C), 153.8 (C), 152.0 (C), 138.9 (CH), 135.4 (CH), 134.6 (C), 
132.3 (C), 122.8 (C), 116.6 (CH2), 114.2 (CH2),  102.5 (CH), 93.9 (CH2), 93.6 (CH2), 
64.5 (CH2), 64.4 (CH2), 46.5 (CH2), 44.8 (CH2), 42.6 (CH2), 36.1 (Me),  33.6 (CH2), 
31.5 (CH2), 28.9 (CH2), 28.8 (CH2), 28.6 (CH2), 23.7 (CH2), 15.0 (Me), 15.0 (Me); 
for the minor isomer, the following NMR signals are discernable, the rest overlap 
with the major isomer: δH (400 MHz; CDCl3) 7.14 (1H, s, ArH), 5.71-5.76 (2H, m, 
CH), 5.31 (1H, d, J 15.4, OCH2O), 3.92 (1H, d, J 17.6, CH2), 3.10 (3H, s, NMe); δC 
(100 MHz; CDCl3) 206.3 (C), 153.9 (C), 152.4 (C), 135.5 (CH), 134.2 (C), 132.4 (C), 
122.3 (C), 117.8 (CH2), 117.6 (CH2), 102.7 (CH), 93.7 (CH2), 93.5 (CH2), 64.4 (CH2), 
46.3 (CH2), 45.2 (CH2), 42.4 (CH2), 32.5 (CH2), 32.1 (CH2), 29.3 (CH2), 28.8 (CH2); 
m/z (ESI) 546 ([M(35Cl)+Na]+, 100%), 547 (28.8%), 548 (34.9%), 549 (7.7%). 
 
15-Chloro-16,18-di(ethoxymethoxy)-2-methyl-3,4,7,8,9,10,11,12-
octahydrobenz[c][1]azacyclohexadecine-1,13(2H,14H)-dione 26c 
 
As for the procedure for compound 26a, using N-(but-3-en-1-yl)-3-chloro-4,6-
di(ethoxymethoxy)-N-methyl-2-(2-oxodec-9-en-1-yl)benzamide 25c (60 mg, 0.11 
mmol, 1.0 eq.). The product was purified by flash column chromatography, eluting 
with 2:1 light petroleum/ethyl acetate to give the title compound as a colourless oil 
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(19 mg, 34%) (4:1 mixture of isomers); (Found: M+Na+, 518.2283. 
C26H3835ClNO6+Na+, requires 518.2280); νmax (CHCl3)/cm−1 3686, 2929, 2856, 1720, 
1627, 1461, 1324, 1278, 1273, 1250, 1151, 1118, 940; major isomer δH (400 MHz; 
CDCl3) 7.08 (1H, s, ArH), 5.49-5.31 (2H, m, CH=CH), 5.30-5.24 (2H, m, OCH2O), 
5.19 (2H, s, OCH2O), 4.40 (1H, ddd, J 13.2, 6.8, 3.2, CH2), 4.03 (1H, d, J 17.3, CH2), 
3.75 (4H, dq, J 14.3, 7.6, OCH2), 3.71-3.66 (2H, m, CH2), 3.59 (1H, d, J 17.3, CH2), 
2.92 (3H, s, NMe), 2.79 (1H, ddd, J 17.8, 15.4, 2.6, CH2), 2.71-2.60 (2H, m, CH2), 
2.55-2.46 (1H, m, CH2), 2.37-2.25 (2H, m, CH2), 2.09-1.98 (2H, m, CH2), 1.97-1.83 
(1H, m, CH2), 1.56-1.43 (2H, m, CH2), 1.41-1.33 (2H, m, CH2), 1.22 (6H, dt, J 13.2, 
7.0, Me); δC (100 MHz; CDCl3) 206.7 (C), 168.2 (C), 153.7 (C), 152.1 (C), 132.6 (C), 
131.7 (CH), 128.0 (CH), 123.6 (C), 117.6 (C), 102.7 (CH), 94.0 (CH2), 93.8 (CH2), 
64.6 (CH2), 64.5 (CH2), 48.2 (CH2), 45.3 (CH2), 40.9 (CH2), 37.8 (Me), 31.1 (CH2), 
30.3 (CH2), 27.0 (CH2), 26.6 (CH2), 25.0 (CH2), 21.7 (CH2), 15.1 (Me), 15.0 (Me); 
for the minor isomer, the following NMR signals are discernable, the rest overlap 
with the major isomer: δH (400 MHz; CDCl3) 4.48 (1H, dt, J 13.3, 7.6, CH2), 3.98 
(1H, d, J 17.7, CH2), 3.87 (1H, d, J 17.7, CH2), 3.23-3.14 (1H,m, CH2), 3.10-3.04 (1H, 
m, CH2), 3.02 (3H, s, NMe), 2.46-2.37 (1H, m, CH2), 1.14-1.03 (1H, m, CH2); δC 
(100 MHz; CDCl3) 206.9 (C), 151.9 (C), 131.9 (CH), 102.7 (CH), 64.5 (CH2), 45.0 
(CH2), 30.6 (CH2), 30.6 (CH2), 27.7 (CH2), 26.3 (CH2); m/z (ESI) 518 ([M(35Cl)+Na]+, 
100%), 519 (28.0%), 520 (33.5%), 521 (8.0%). 
15-Chloro-16,18-dihydroxy-2-methyl-3,4,7,8,9,10,11,12-
octahydrobenz[c][1]azacyclohexadecine-1,13(2H,14H)-dione 27c 
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As for the procedure for compound 27a, using 15-chloro-16,18-di(ethoxymethoxy)-2-
methyl-3,4,7,8,9,10,11,12-octahydrobenzo[c][1]azacyclohexadecine-1,13(2H,14H)-
dione 26c (15 mg, 0.33 mmol, 1 eq.). The product was purified by flash column 
chromatography, eluting with 2% methanol/dichloromethane to give the title 
compound as a colourless solid (4 mg, 33%) (5:1 mixture of isomers); mp 204-206 °C; 
(Found: M+Na+, 402.1442. C20H2635ClNO4+Na+, requires 402.1443); νmax 
(CHCl3)/cm−1 3440, 3280, 2613, 1710, 1720, 1702, 1630, 1450, 1430, 1413, 1369, 
1334, 1252, 1096; major isomer δH (800 MHz; acetone-d6) 8.68 (1H, s, OH), 8.65 
(1H, br. s, OH), 6.56 (1H, s, ArH), 5.44-5.41 (2H, m, CH=CH), 4.32-4.28 (1H, m, 
CH2), 3.88 (1H, d, J 17.1, CH2), 3.67 (1H, d, J 17.1, CH2), 2.94 (3H, s, NMe), 2.77-
2.72 (1H, m, CH2), 2.67 (1H, ddd, J 17.5, 9.4, 2.6, CH2), 2.59-2.53 (1H, m, CH2), 
2.53-2.45 (1H, m, CH2), 2.32-2.28 (1H, m, CH2), 2.02-1.98 (1H, m, CH2), 1.84-1.77 
(1H, m, CH2), 1.54-1.48 (1H, m, CH2), 1.48-1.42 (1H, m, CH2), 1.41-1.34 (2H, m, 
CH2), 1.32-1.25 (2H, m, CH2), 1.25-1.21 (1H, m, CH2), 1.17-1.10 (1H, m, CH2); δC 
(200 MHz; acetone-d6) 207.4 (C), 169.8 (C), 155.3 (C), 154.3 (C), 134.8 (C),  132.8 
(C), 130.7 (CH), 129.4 (CH) 114.4 (C), 104.2 (CH), 49.5 (CH2), 47.0 (CH2), 41.7 
(CH2), 38.6 (Me), 32.9 (CH2), 32.1 (CH2),  28.8 (CH2), 28.3 (CH2), 26.6 (CH2), 23.3 
(CH2); for the minor isomer, the following NMR signals are discernable, the rest 
overlap with the major isomer: δH (800 MHz; acetone-d6) 8.70 (1H, s, OH), 6.55 (1H, 
s, ArH), 3.96 (1H, d, J 17.8, CH2), 2.91 (3H, s, NMe), 2.63-2.55 (1H, m, CH2), 2.47-
2.40 (1H, m, CH2), 2.40-2.35 (1H, m, CH2), 2.20-2.14 (1H, m, CH2), 1.80-1.72 (1H, 
m, CH2), 1.64-1.57 (1H, m, CH2), 1.36-1.28 (1H, m, CH2); δC (200 MHz; acetone-d6) 
122.2 (CH), 104.1 (CH), 101.9 (C), 56.0 (CH2), 31.6 (CH2), 31.3 (CH2), 27.9 (CH2), 
26.8 (CH2);  m/z (ESI) 402 ([M(35Cl)+Na]+, 100%), 403 (21.9%), 404 (32.4%), 405 
(6.8%). 
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N-(Pent-4-en-1-yl)-3-chloro-4,6-di(ethoxymethoxy)-N-methyl-2-(2-oxohept-6-en-
1-yl)benzamide 25d 
 
As for the procedure for compound 25a, using 3-chloro-4,6-di(ethoxymethoxy)-2-
methylbenzoic acid 23 (200 mg, 0.63 mmol, 1 eq.), N-methoxy-N-methylhex-5-
enamide (148 mg, 0.94 mmol, 1.5 eq.) and N-methylpent-4-en-1-amine (91 mg, 0.68 
mmol, 1.5 eq.). The product was purified by flash column chromatography, eluting 
with 4:1 light petroleum/ethyl acetate to give the title compound as a yellow oil (81 
mg, 28% over 2 steps) (3:1 mixture of isomers); (Found: M+Na+, 518.2281 
C26H3835ClNO6+Na+, requires 518.2280); νmax (CHCl3)/cm−1 3686, 3600, 3058, 2996, 
1719, 1628, 1597, 1458, 1408, 1319, 1278, 1265, 1152, 1119, 1042, 941, 896; major 
isomer δH (400 MHz; CDCl3) 7.11 (1H, s, ArH), 5.92-5.72 (2H, m, CH), 5.32 (1H, d, 
J 13.2, OCH2O), 5.30 (1H, d, J 13.2, OCH2O), 5.22 (2H, s, OCH2O), 5.10-4.93 (4H, 
m, =CH2), 4.03 (1H, d, J 17.7, CH2), 3.86 (1H, d, J 17.7, CH2), 3.82-3.77 (2H, m, 
OCH2), 3.76-3.66 (2H, m, OCH2), 2.85 (3H, s, NMe), 2.54 (2H, ddd, J 15.0, 7.4, 3.0 
CH2), 2.35-2.29 (1H, m, CH2), 2.20-2.06 (6H, m, CH2), 1.77-1.68 (6H, m, CH2), 1.23 
(6H, dt, J 8.3, 7.1, Me); δC (100 MHz; CDCl3) 206.4 (C), 167.5 (C), 153.8 (C), 152.1 
(C), 137.9 (CH), 137.8 (CH), 132.3 (C), 122.9 (C), 117.7 (C), 115.3 (CH2), 115.1 
(CH2), 102.6 (CH), 94.0 (CH2), 93.7 (CH2), 64.6 (CH2), 64.5 (CH2), 46.5 (CH2), 44.8 
(CH2), 41.8 (CH2), 35.9 (Me),  33.0 (CH2), 30.9 (CH2), 26.2 (CH2), 22.9 (CH2), 15.0 
(Me), 15.0 (Me); for the minor isomer, the following NMR signals are discernable, 
the rest overlap with the major isomer: δH (400 MHz; CDCl3) 7.15 (1H, s, ArH), 5.33 
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(1H, d, J 13.8, O-CH2-O), 5.31 (1H, d, J 13.8, O-CH2-O), 5.20 (2H, s, O-CH2-O), 
3.91 (1H, d, J 17.0, CH2),  3.64-3.55 (2H, m, O-CH2), 3.50-3.40 (2H, m, O-CH2),  
3.07 (3H, s, NMe), 2.54 (2H, ddd, J 15.0, 7.4, 3.0 CH2), 1.98-1.91 (1H, m, CH2); δC 
(100 MHz; CDCl3) 206.6 (C), 138.0 (CH), 137.4 (CH), 115.2 (CH2), 102.8 (CH), 41.5 
(CH2), 30.8 (CH2), 22.8 (CH2); m/z (ESI) 518 ([M(35Cl)+Na]+, 100%), 519 (24.9%), 
520 (32.6%), 521 (7.6%). 
 
13-Chloro-14,16-di(ethoxymethoxy)-2-methyl-2,3,4,5,9,10-
hexahydrobenz[c][1]azacyclotetradecine-1,11(8H,12H)-dione 26d 
 
As for the procedure for compound 26a,  using N-(pent-4-en-1-yl)-3-chloro-4,6-
di(ethoxymethoxy)-N-methyl-2-(2-oxohept-6-en-1-yl)benzamide 25d (0.081 g, 0.176 
mmol, 1 eq.). The product was purified by flash column chromatography, eluting with 
1% methanol/dichloromethane to give the title compound as a yellow oil (0.056 g, 
68%) (9:1 mixture of isomers); (Found: M+Na+, 490.1965. C24H3435ClNO6+Na+, 
requires 490.1967); νmax (CHCl3)/cm−1 3688, 3005, 2930, 2361, 2341, 1719, 1626, 
1597, 1456, 1422, 1319, 1150, 1051, 941, 909; major isomer δH (400 MHz; CDCl3) 
7.10 (1H, s, ArH), 5.52 (2H, dt, J 9.9, 5.8, CH=CH), 5.28 (1H, d, J 15.8 OCH2O), 
5.27 (1H, d, J 15.8 OCH2O),  5.20 (2H, s, OCH2O), 4.45 (1H, ddd, J 13.3, 6.9, 3.7, 
CH2), 4.08 (1H, d, J 18.6, CH2), 3.90 (1H, d, J 18.6, CH2),  3.76 (2H, q, J 7.1, OCH2), 
3.69 (2H, q, J 7.1, OCH2), 2.86 (3H, s, NMe), 2.69-2.61 (2H, m, CH2), 2.45 (1H, ddd, 
J 18.5, 6.0, 2.2 CH2), 2.36-2.27 (1H, m, CH2), 2.11-2.00 (2H, m, CH2), 1.93-1.77 (2H, 
m, CH2), 1.73-1.61 (3H, m, CH2), 1.22 (6H, dt, J 8.3, 7.1, Me); δC (100 MHz; CDCl3) 
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205.6 (C), 167.9 (C), 153.7 (C), 151.8 (C), 131.9 (C), 130.7 (CH), 128.7 (CH), 123.0 
(C), 118.0 (C), 102.6 (CH), 93.9 (CH2), 93.7 (CH2), 64.5 (CH2), 64.4 (CH2), 47.4 
(CH2), 44.8 (CH2), 38.5 (CH2), 37.5 (Me), 28.5 (CH2), 25.1 (CH2), 24.6 (CH2), 21.6 
(CH2), 15.0 (Me), 15.0 (Me); for the minor isomer, the following NMR signals are 
discernable, the rest overlap with the major isomer: δH (400 MHz; CDCl3) 7.08 (1H, s, 
ArH), 5.32-5.25 (2H, m, OCH2O), 5.19 (2H, s, OCH2O), 4.05 (1H, d, J 18.0, CH2), 
2.88 (3H, s, NMe); m/z (ESI) 490 ([M(35Cl)+Na]+, 100%), 491 (23.5%), 493 (33.3%), 
494 (6.6%). 
 
13-Chloro-14,16-dihydroxy-2-methyl-2,3,4,5,9,10-
hexahydrobenz[c][1]azacyclotetradecine-1,11(8H,12H)-dione 27d 
 
As for the procedure for compound 27a, using 13-chloro-14,16-di(ethoxymethoxy)-2-
methyl-2,3,4,5,9,10-hexahydrobenz[c][1]azacyclotetradecine-1,11(8H,12H)-dione 
26d (52 mg, 0.111 mmol, 1 eq.). The product was purified by flash column 
chromatography, eluting with 2% methanol/dichloromethane to give the title 
compound as a yellow solid (11 mg, 28%) (4:1 mixture of isomers); mp 178-180 °C; 
(Found: M+Na+, 374.1138. C18H2235ClNO4+Na+, requires 374.1130); νmax 
(CHCl3)/cm−1 3483, 3280, 1730, 1723, 1708, 1630, 1435, 1419, 1396, 1376, 1334, 
1249, 12191, 1094;  major isomer δH (800 MHz; acetone-d6) 8.75 (1H, s, OH), 8.66 
(1H, s, OH), 6.58 (1H, s, ArH), 5.55 (1H, dt, J 10.6, 5.6, CH), 5.33 (1H, dt, J 10.6, 5.6, 
CH), 4.35-4.31 (1H, m, CH2), 4.05 (1H, d, J 18.6, CH2), 3.97 (1H, d, J 18.6, CH2), 
2.91 (3H, s, NMe), 2.72-2.64 (2H, m, CH2), 2.57-2.52 (1H, m, CH2), 2.39-2.34 (1H, 
dt, J 11.4, 9.9, CH2), 2.10-2.05 (1H, m, CH2), 2.02-1.96 (1H, m, CH2), 1.92-1.85 (2H, 
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m, CH2), 1.71-1.66 (1H, m, CH2), 1.64-1.58 (1H, m, CH2), 1.34-1.29 (1H, m, CH2); 
δC (200 MHz; acetone-d6) 205.8 (C), 168.6 (C), 154.2 (C), 152.8 (C), 133.3 (C), 131.9 
(CH), 129.3 (CH), 120.9 (C), 113.9 (C), 103.1 (CH), 47.9 (CH2), 45.1 (CH2), 38.9 
(CH2), 37.5 (Me), 29.5 (CH2), 25.9 (CH2), 25.5 (CH2), 22.5 (CH2); for the minor 
isomer, the following NMR signals are discernable, the rest overlap with the major 
isomer: δH (800 MHz; acetone-d6) 8.86 (1H, s, OH), 8.57 (1H,s, OH), 6.82 (1H, s, 
ArH), 5.42-5.36 (1H, m, CH), 5.30-5.22 (1H, m, CH), 4.08 (1H, d, J 18.6, CH2), 2.51-
2.46 (1H, m, CH2), 2.23-2.19 (1H, m, CH2), 2.16-2.13 (1H, m, CH2); δC (200 MHz; 
acetone-d6) 154.3 (C), 152.6 (C), 133.4 (C), 103.2 (CH), 30.6 (CH2), 21.5 (CH2); m/z 
(ESI) 374 ([M(35Cl)+Na]+, 100%), 375 (17.7%), 376 (30.6%), 377 (6.2%). 
Isothermal Titration Calorimetry (ITC) 
ITC was carried out as previously described by Proisy and co-workers.16 Briefly, 
heats of the interaction were measured at 30 °C on an ITC200 (GE healthcare), with a 
cell volume of 200 µL. Ten injections of 3.8 µL of 600 µM of radicicol or radicicol 
analogue, in 20 mM Tris, 5 mM NaCl, 1 mM EDTA and 2% DMSO, were injected 
into 40 µM yeast Hsp90 N-terminal domain in the same buffer. Heats of dilution were 
determined in a separate experiment by injecting compound into buffer containing 2% 
DMSO, and the corrected data were fit with a nonlinear least square curve-fitting 
algorithm (Microcal Origin) with three floating variables: stoichiometry, binding 
constant, and change in enthalpy of interaction. 
 
Protein co-Crystallisation Experimental 
The expression, purification and co-crystallisation of the N-terminal domain of yeast 
Hsp90 have been previously described.51 Single crystals appeared overnight of 
approximate dimensions 0.3 mm × 0.2 mm × 0.2 mm. These were flash frozen after 
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stepwise addition of glycerol to 30%, and the data were collected on station I02 at 
Diamond Light Source. The data were integrated and scaled using the automatic 
Xia252, 53 processing at Diamond. 
 
The complexes were initially solved by isomorphous replacement using a previously 
determined N-terminal structure (PDB 1AH6) in the usual space group, P4
3
22. The 
model was refined using REFMAC54 and rebuilt using COOT.55 The inhibitors were 
built using the PRODRG server.56 The inhibitor molecule and the waters were added 
in the final stages. Various programs from the CCP457 suite were used during the 
refinement. All refinements proceeded smoothly. The crystallographic statistics are 
given in Table 2. 
 
Table 2. Crystallographic data 
Data Set 
(Highest shell in 
parentheses) 
27b 27c 27d 
    
a (Å) 74.32 74.16 74.18 
b (Å) 74.32 74.16 74.18 
c (Å) 110.46 110.43 110.49 
α (°) 90 90 90 
β (°) 90 90 90 
γ (°) 90 90 90 
Space Group P 43 2 2 P 43 2 2 P 43 2 2 
Wavelength (Å) 0.97961 0.97961 0.97961 
Resolution Limit (Å) 47.5-2.38 
(2.45-2.38) 
52.4-2.01 
(2.06-2.01) 
52.5-2.31 
(2.37-2.31) 
Number of Obs. 12939 
(927) 21192 (1511) 
13834 
(1002) 
Completeness (%) 99.9 
(100.0) 99.9 (99.8) 
98.8 
(98.3) 
Multiplicity 8.5 (9.0) 8.5 (9.0) 3.8 (3.9) 
Rmerge 0.111 (0.803) 0.065 (0.720) 0.071 (0.676) 
Rpim(I) 0.043 (0.301) 0.024 (0.263) 0.035 (0.318) 
I/σI 14.2 (2.8) 20.4 (3.5) 17.5 (2.5) 
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Refinement    
    
Resolution Range (Å) 47.5-2.38 52.4-2.01 52.5-2.32 
Rcryst 0.1930 0.2058 0.1933 
Rfree 0.2394 0.2660 0.2613 
    
Number of protein 
atoms 1691 1690 1675 
Number of ligand 
atoms 25 26 24 
Number of solvent 
atoms 126 115 113 
    
Mean B 42.4 36.5 39.7 
Rmsd bond lengths (Å) 0.016 0.018 0.016 
Rmsd bond angles (°) 1.848 1.935 1.802 
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